Mesenchymal Stem Cell Therapy in Multiple System Atrophy

Phase 1/2 Active not recruiting 30 enrolled Mayo Clinic Food and Drug Administration (FDA) · collab National Institute of Neurological Disorders and Stroke (NINDS) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.

Timeline

Start: 2012-10
Primary completion: 2027-03
Completion: 2027-03

Publications

Camilleri ET, Gustafson MP, Dudakovic A, Riester SM, Garces CG, Paradise CR, Takai H, Karperien M, Cool S, Sampen HJ, Larson AN, Qu W, Smith J, Dietz AB, van Wijnen AJ. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016 Aug 11;7(1):107. doi: 10.1186/s13287-016-0370-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous mesenchymal stem cells	Cell therapy	1e+07 cells	Intrathecal
Subject	Autologous mesenchymal stem cells	Cell therapy	2.5e+07 cells	Intrathecal
Subject	Autologous mesenchymal stem cells	Cell therapy	5e+07 cells	Intrathecal
Subject	Autologous mesenchymal stem cells	Cell therapy	1e+08 cells	Intrathecal

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

Summary

Timeline

Publications

Drugs

Indications